Filing Flows › Cue Biopharma (CUE) › Q2 2026
Cue Biopharma (CUE) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 14, 2026
Cue Biopharma (CUE) reported revenue of $7.9M for the second quarter 2026 (Q2 2026), +167% from a year earlier and +39% from the quarter before.
Cue Biopharma, Q2 2026: revenue $7.9M (+167% year over year), net loss $153M, operating cash flow −$29.0M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $7.9M | +39% | +167% |
| Operating profit | −$87.7M | — | — |
| Net earnings | −$153M | — | — |
| Operating cash flow | −$29.0M | — | — |
What changed
Revenue was $7.9M in Q2 2026, up 167% year over year and up 39% from the previous quarter.
Operating costs exceeded revenue by $87.7M, an operating margin of -1113.3%. Total costs grew 725% against revenue growth of 167%. The fastest-growing cost line was General & admin (+1166%). The quarter ended with a net loss of $153.1M, wider than the previous quarter's $5.2M loss.
Operating cash flow was −$29.0M. Non-cash charges added back $36K of depreciation and amortization and $23.8M of share-based compensation. Working capital and other items added $100.2M.
Questions
What was Cue Biopharma's revenue in the second quarter 2026?
Cue Biopharma (CUE) reported revenue of $7.9M for the second quarter 2026 (Q2 2026), +167% from a year earlier and +39% from the quarter before.
Source: Cue Biopharma 10-Q on SEC EDGAR.